Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montréal, Quebec, Canada.
Hematol Oncol. 2010 Sep;28(3):142-50. doi: 10.1002/hon.935.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy with a variable response to therapy. We have previously shown that DLBCL cell lines differ in their susceptibility to CD40-mediated cell death, and that resistance to CD40-targeted antibodies correlated with increased expression of markers of immature B-cell and absence of Vav-1 mRNA. We used gene expression profiling to investigate the mechanism of CD40 resistance in these cell lines, and found that resistance correlated with lack of Vav-1 and inability to activate NFκB upon CD40 ligation. Analysis of tissue microarrays of 213 DLBCL cases revealed that Vav-1 expression correlated with a higher proliferative index and the presence of the post-germinal centre marker Irf-4. Our results suggest that Vav-1 expression may be associated with activated B-cell DLBCL origin and higher proliferative activity, and indicate Vav-1 as a potential marker to identify tumours likely to respond to CD40-targeted therapies.
弥漫性大 B 细胞淋巴瘤(DLBCL)是一种侵袭性恶性肿瘤,对治疗的反应存在差异。我们之前已经表明,DLBCL 细胞系对 CD40 介导的细胞死亡的敏感性不同,并且对 CD40 靶向抗体的耐药性与不成熟 B 细胞标志物的表达增加和 Vav-1 mRNA 的缺失相关。我们使用基因表达谱分析来研究这些细胞系中 CD40 耐药的机制,发现耐药性与缺乏 Vav-1 和 CD40 交联时无法激活 NFκB 有关。对 213 例 DLBCL 病例的组织微阵列分析表明,Vav-1 表达与更高的增殖指数和生发中心后标记物 Irf-4 的存在相关。我们的结果表明,Vav-1 表达可能与激活的 B 细胞 DLBCL 起源和更高的增殖活性相关,并表明 Vav-1 可作为潜在的标志物,用于识别可能对 CD40 靶向治疗有反应的肿瘤。